Ideaya Biosciences Inc
0.0 %
-60.59 %
Yet to be announced
Company Overview
IDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine oncology company. The company's primary focus is on discovering and developing targeted therapeutics for patient populations selected using molecular diagnostics. They are developing potential treatments for various types of cancers using synthetic lethality, targeting specific genetic mutations.
The company is currently in the clinical development stage, with several drug candidates in their pipeline targeting various cancer indications. Their lead programs include IDE397, a MAT2A inhibitor, and darovasertib, a PKC inhibitor.
Revenue Sources
PassIDEAYA Biosciences is a clinical-stage biotechnology company focused on developing cancer treatments. The company is still primarily in research and development phase, with minimal revenue generation. Their revenue sources are primarily from collaboration agreements and research partnerships, which are halal activities.
Given that the company is pre-revenue and mainly focused on R&D activities, with any current revenue coming from legitimate research collaborations, there is no indication of revenue from haram sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $7.0m | $151.14m | - | - | 0.00% | 0.00% |
Based on the financial data provided for the last four quarters, the company shows zero interest income and zero interest expense. The company is still in the pre-revenue phase, focusing on research and development of cancer treatments. Since the company is pre-revenue and in R&D mode, we skip the interest ratio calculations as they would not be meaningful at this stage of company development.
Operational Ethics
PassAfter reviewing the company's SEC filings, investor relations materials, and public information, there is no evidence of any significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States, with no indication of R&D centers or significant operations in Israel or direct involvement with the Chinese Communist Party.
Comments